Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face of a tough market environment.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Healthcare has dislodged technology as the worst-performing sector of the S&P/TSX Composite Index. As of June 15, 2022, the year-to-date loss has risen to 48.54%. It isn’t surprising, because most of the sector’s constituents are cannabis stocks.

Industry leader Canopy Growth (-58.88%), along with Tilray (-53.70%) and Cronos (-29.32%), are in negative territory. However, Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) has fallen into the abyss. From $5.41 per share on year-end 2021, the price plunged 75.05% to $1.35. What ails the cannabis cultivator and producer? Is the stock with liquidity issues worth buying at a rock-bottom price?

Scarce cash flows

Cash is king, but it seems that Aurora Cannabis has difficulty generating money. Some market analysts say the $402.25 million company might even run out of money in one year. The revenue numbers thus far in fiscal 2022 do not look good. While medical cannabis’s net revenue increased 8% in Q3 fiscal 2022 versus Q2 fiscal 2022, total net revenue declined 17% to $60.58 million.

Aurora serves the medical and consumer markets, but the net revenue of the latter declined 43% compared to Q3 fiscal 2021. Its CEO, Miguel Martin, said, “We continue to steer our differentiated global cannabis business towards long-term shareholder value creation.”

Martin added, “During Q3, we continued focusing on our global medical cannabis business because it is both defensive and stable, with cash gross margins that exceed 60%.” According to the CEO, the segment’s considerable top-line growth is encouraging, and he is also confident that opening new international markets positions Aurora for a significant revenue opportunity globally.

Management’s statement reads, “We believe that cannabis growth over the next several years will center on the international medical and recreational markets.” It noted the early success in the markets of Australia, Israel, and Europe. For Aurora, its roots in the medical industry, deep experience in federally regulated markets, and leadership in science and plant genetics are differentiating factors.

Swelling costs

Aurora is paying the price for its spending spree to become the world’s largest cannabis producer. Today, management sees the need to implement drastic cost-cutting measures. One route to profitability is to reduce production capacity. Its transformational plan includes selling its flagship Aurora Sky facility in Edmonton.

While the facility was supposed to have production power (230,000 kilograms annually), the cannabis market in Canada can’t support it. The project is partially complete, and the construction has been suspended. Two more facilities will close by the fourth quarter of this year. Aurora’s net loss in Q3 fiscal 2022 reached more than $1 billion.

Share dilution

Share dilution is a nightmare to some investors, as Aurora continues to execute deal financing agreements to raise the much-needed cash. Some observers think the company’s capital-raising plan signifies desperation. Furthermore, Aurora will use the funds for general corporate purposes, not growth investments.

Lacking in catalysts

Aurora Cannabis is neck-deep in problems such as weak revenue growth, over capacity, negative cash flows, and pricing pressures. If you’re considering taking a position in this struggling cannabis stock, hold the thought. The company is notorious for its cash-burning business. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Monday, May 30

TSX investors should keep a close eye on the latest manufacturing data from China today.

Read more »